2022
Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery
Garcia-Nebreda M, Zorrilla-Vaca A, Ripollés-Melchor J, Abad-Motos A, Alvaro Cifuentes E, Abad-Gurumeta A, Mena G, Grant M, Paseiro-Crespo G. Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery. Langenbeck's Archives Of Surgery 2022, 407: 2293-2300. PMID: 35441358, DOI: 10.1007/s00423-022-02515-7.Peer-Reviewed Original ResearchConceptsGastric cancer surgeryCancer surgeryERAS pathwayAdjuvant therapySurgery pathwayOncologic therapyGastric adenocarcinomaEnhanced recoveryPostoperative oncologic outcomesPre-ERAS periodERAS groupHospital stayOncologic outcomesPrimary outcomeShorter LOSResultsSeventy patientsEarly returnSurgeryIntervention studiesTherapyPatientsMedian differenceAdenocarcinomaOutcomesPathwayMultimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data
Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Frontiers In Cardiovascular Medicine 2022, 9: 829553. PMID: 35369354, PMCID: PMC8964995, DOI: 10.3389/fcvm.2022.829553.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMagnetic resonance imagingExtracellular volumeEarly detectionImmune checkpoint inhibitionWall motion abnormalitiesCancer therapyMechanisms of cardiotoxicityTyrosine kinase inhibitorsCurrent imaging modalitiesAssessment of functionCardioprotective medicationsCardiotoxic eventsMolecular radiotracersCardiovascular outcomesMolecular imagingCheckpoint inhibitionNovel cancer therapiesOncologic therapyCancer mortalityMyocardial infarctionMotion abnormalitiesCardiac metabolismCardiotoxicityResonance imagingTherapy
2017
Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersShould Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System.
Adelson K, Stutsky M, Fradkin M, Harrison M, Abdelghany O, Morrow B, Smith M, Havriliak R, Kregling S, Lyons C, Chiang A, Cohen H. Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System. Journal Of Clinical Oncology 2017, 35: 108-108. DOI: 10.1200/jco.2017.35.8_suppl.108.Peer-Reviewed Original ResearchMedication assistance programsOral chemotherapy programChemotherapy programSpecialty pharmacyYale New Haven Health SystemHealth systemClinical oncology pharmacistSmilow Cancer HospitalPatient assistance programsMultidisciplinary task forceSpecialty pharmacistsCollaborative Improvement ModelHealth-system pharmacyOral chemotherapyCancer HospitalCancer CenterOncologic therapyPrescription errorsOncology pharmacistsTreatment protocolHigh riskPatient callsSpecialty servicesOncologic processesDay 1
2016
Chapter 27 Current and future immunotherapy targets in autoimmune neurology
Hu MY, Stathopoulos P, O’connor K, Pittock SJ, Nowak RJ. Chapter 27 Current and future immunotherapy targets in autoimmune neurology. Handbook Of Clinical Neurology 2016, 133: 511-536. PMID: 27112694, DOI: 10.1016/b978-0-444-63432-0.00027-x.ChaptersConceptsAutoimmune neurologic disordersNeurologic disordersChronic inflammatory demyelinating polyradiculoneuropathyInflammatory demyelinating polyradiculoneuropathyPrior treatment responseLarge case seriesAbsence of cancerAutoimmune neurologyChronic immunotherapyDemyelinating polyradiculoneuropathyMyasthenia gravisNeuromyelitis opticaCase seriesOncologic therapyTreatment trialsImmunotherapy targetClinical severityTreatment strategiesTreatment responseAntibody typeMonoclonal antibodiesAnecdotal reportsNew drug discoveryDisordersImmunotherapy
2010
Management of a parturient with high-grade osteosarcoma of the proximal femur: a multidisciplinary approach
Quaye A, Raskin K, Ecker J, Leffert L. Management of a parturient with high-grade osteosarcoma of the proximal femur: a multidisciplinary approach. International Journal Of Obstetric Anesthesia 2010, 19: 340-342. PMID: 20627530, DOI: 10.1016/j.ijoa.2010.03.013.Peer-Reviewed Original ResearchConceptsHigh-grade osteosarcomaCommon primary malignant bone tumorPrimary malignant bone tumorWeeks of gestationMalignant bone tumorsNewborn baby boyFemoral neck resectionAdjuvant chemotherapyCesarean deliveryMultiparous womenPathologic fractureSpinal anesthesiaSubsequent surgeryLimb salvageThird trimesterOncologic therapyBone tumorsMultidisciplinary planningNeck resectionBaby boyProximal femurOsteosarcomaMultidisciplinary approachPregnancyMothers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply